Статья

Evaluation of A(H1N1)pdm09 LAIV vaccine candidates stability and replication efficiency in primary human nasal epithelial cells

S. Shcherbik, N. Pearce, P. Carney, E. Bazhenova, N. Larionova, I. Kiseleva, L. Rudenko, A. Kumar, C. Goldsmith, V. Dugan, J. Stevens, D. Wentworth, T. Bousse,
2021

The recent reduction of live attenuated influenza vaccine (LAIV) effectiveness in multivalent formulations was particularly associated with the A(H1N1)pdm09 component. In the 2017 the WHO vaccine composition committee changed its recommendations for the A(H1N1)pdm09 component to include an A/Michigan/45/2015-like virus. We evaluated effectiveness and quality of newly developed and previous A(H1N1)pdm09 LAIV reassortants through assessment of their thermal and pH stability, receptor binding specificity and replication fitness in primary human airway epithelial cells of nasal origin (hAECN). Our analysis showed that LAIV expressed hemagglutinin (HA) and neuraminidase (NA) from an A/Michigan/45/2015-like strain A/New York/61/2015 (A/New York/61/2015-CDC-LV16A, NY-LV16A), exhibit higher thermal and pH stability compared to the previous vaccine candidates expressing HA and NA from A/California/07/2009 and A/Bolivia/559/2013 (A17/Cal09 and A17/Bol13). Reassortants A/South Africa/3626/2013-CDC-LV14A (SA-LV14A) and NY-LV16A showed preferential binding to α2,6 sialic acid (SA) receptors and replicated at higher titers and more extensively in hAECN compared to A17/Cal09 and A17/Bol13, which had an α2,3 SA receptor binding preference. Our data analysis supports selection of A/New York/61/2015-CDC-LV16A for LAIV formulation and the introduction of new assays for LAIV characterization. © 2019 The Author(s)

Цитирование

Похожие публикации

Документы

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • S. Shcherbik
    Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States
  • N. Pearce
    Battelle, Atlanta, GA 30329, United States
  • P. Carney
    Institute of Experimental Medicine, Department of Virology, St. Petersburg, Russian Federation
  • E. Bazhenova
    Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States
  • N. Larionova
  • I. Kiseleva
  • L. Rudenko
  • A. Kumar
  • C. Goldsmith
  • V. Dugan
  • J. Stevens
  • D. Wentworth
  • T. Bousse
Название журнала
  • Vaccine: X
Том
  • 2
Страницы
  • -
Ключевые слова
  • influenza vaccine; Influenza virus hemagglutinin; virus sialidase; airway epithelium cell; animal cell; Article; binding affinity; controlled study; drug antigenicity; drug receptor binding; embryo; genetic reassortment; human; human cell; Influenza A virus (H1N1); Mustela putorius furo; nonhuman; nose epithelium; pH; priority journal; thermostability; virogenesis; virus replication; virus strain
Издатель
  • Elsevier Ltd
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus